{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["45"],"submitter":["Muller-Jensen L"],"pubmed_abstract":["Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited. We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis - two alternative causes of encephalitis - to increase the awar"],"journal":["Data in brief"],"pagination":["108649"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9679487"],"repository":["biostudies-literature"],"pubmed_title":["Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis."],"pmcid":["PMC9679487"],"pubmed_authors":["Soon JA","Tahara M","Salzmann M","Kahler KC","Hassel JC","Enokida T","Zierold S","Endres M","Mohr R","Reinhardt L","Schoberl F","Zimmer L","Meier F","Hagenacker T","Schlaak M","Knauss S","Spain L","Gesierich A","Boehmerle W","Hundsberger T","Heinzerling LM","Banks P","Ugurel S","Blank CU","Compter A","Versluis JM","Seggewiss-Bernhardt R","Long GV","von Baumgarten L","French LE","Harvey C","Muller-Jensen L","Huehnchen P"],"additional_accession":[]},"is_claimable":false,"name":"Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.","description":"Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited. We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis - two alternative causes of encephalitis - to increase the awar","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-06-01T12:01:54.59Z","creation":"2024-12-04T01:42:17.861Z"},"accession":"S-EPMC9679487","cross_references":{"pubmed":["36426082"],"doi":["10.1016/j.dib.2022.108649"]}}